Cellectar reports financial results for year ended december 2021 and provides a corporate update

Florham park, n.j., march 21, 2022 (globe newswire) -- cellectar biosciences, inc. (nasdaq: clrb), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of targeted drugs for the treatment of cancer, today announced financial results for the year ended december 31, 2021 and provided a corporate update.
CLRB Ratings Summary
CLRB Quant Ranking